Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Tory Sullivan MD Pa

Neither a doctor nor a teaching hospital

Research payments

$704,904

105 payments

Through program year 2025, Tory Sullivan MD Pa is reported as receiving $704,904 in research payments, across 105 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $65,794 11
2024 Research $68,163 21
2023 Research $297,070 38
2022 Research $84,317 8
2021 Research $73,282 6
2020 Research $12,851 6
2019 Research $103,427 15

Breakdown

Who paid Research payments · program years 2019–2025
  1. Janssen Research & Development, LLC $231,760 36 payments
  2. Bausch Health US, LLC $191,043 24 payments
  3. AbbVie, Inc. $64,777 8 payments
  4. Pfizer Inc. $57,410 17 payments
  5. Acrotech Biopharma LLC $50,112 9 payments
  6. Eli Lilly and Company $49,798 5 payments
  7. Novartis Pharmaceuticals Corporation $42,072 2 payments
  8. Amgen Inc. $12,457 1 payment
  9. Arcutis Biotherapeutics, Inc. $4,970 1 payment
  10. Ucb SA $506 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. Cnto1959pso3018 $180,227 27 payments
  2. Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Efficacysafety Study $90,540 10 payments
  3. A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Clinical Study to Compare the Safety and Efficacy of Idp-126 Gel to Epiduo? Forte Gel (0.3% Adapalene/2.5% Bpo), in the Treatment of Acne Vulgaris $76,422 7 payments
  4. Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/?or Scalp Psoriasis (VISIBLE) $51,533 9 payments
  5. A Phase 23 Twopart Study to Evaluate the Efficacy and Longterm Safety With Oral Etrasimod 2 MG Once Daily in Adult Participants With Moderatetosevere Atopic Dermatitis With A History of Prior Systemic Treatment Failure $43,338 11 payments
  6. An Open-Label Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants With Moderate-To-Severe Atopic Dermatitis Previously Treated With Dupilumab $39,914 2 payments
  7. A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) $34,475 3 payments
  8. 246-13651-302 $30,664 5 payments
  9. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Remibrutinib (Lou064) to Investigate the Efficacy, Safety and Tolerability for 52 Weeks in Adult Chronic Spontaneous Urticaria (Csu) Patients Inadequately Controlled By H1-Antihi $30,476 1 payment
  10. A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) $30,302 5 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record